Results 11 to 20 of about 177,018 (304)

Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?

Hematology/Oncology and Stem Cell Therapy, 2022
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3Z activatory domain connected to 4-1BB costimulatory domain.
Mohamed A. Kharfan-Dabaja, Farah Yassine, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant Murthy   +4 more
doaj   +1 more source

CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models

OncoImmunology, 2020
In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antigen Her2 (human epidermal growth factor receptor-2) to B cells via the anti-CD19 single chain variable fragment (scFv) was shown to augment tumor-specific ...
Zhuangwei Lv, Ping Zhang, Dandan Li, Mengting Qin, Longzhu Nie, Xiaoqian Wang, Li Ai, Zhaozu Feng, Woodvine Otieno Odhiambo, Yunfeng Ma, Yanhong Ji   +10 more
doaj   +1 more source

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor, Crawford, Dorothy, Gilham, David, Johannessen, Ingolfur, Swanson, Anna, Talbot, Simon   +5 more
core   +1 more source

Purification and Immunophenotypic Characterization of Human CD19+CD24hiCD38hi and CD19+CD24hiCD27+ B Cells [PDF]

, 2021
Regulatory B cells (Bregs) have immunosuppressive capacity, primarily via the production of IL-10. IL-10 expression and immunosuppression have been described in a number of human B cell subsets, two of which include the CD19+CD24hiCD38hi and CD19+CD24hiCD27+ populations.
Bradford, HF, Mauri, C
openaire   +3 more sources

Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients

Turkish Journal of Hematology, 2020
Objective: Relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) are the focus of studies on hematological cancers.
Cihan Taştan, Derya Dilek Kançağı, Raife Dilek Turan, Bulut Yurtsever, Didem Çakırsoy, Selen Abanuz, Muhammet Yılancı, Utku Seyis, Samed Özer, Selin Mert, Cavit Kerem Kayhan, Fatma Tokat, Merve Açıkel Elmas, Selçuk Birdoğan, Serap Arbak, Koray Yalçın, Aslıhan Sezgin, Ebru Kızılkılıç, Cansu Hemşinlioğlu, Ümit İnce, Siret Ratip, Ercüment Ovalı   +21 more
doaj   +1 more source

Efficient Transduction of T-Lymphocytes by Lentiviral Particles in Oncoimmunological Studies

Клиническая онкогематология, 2020
Aim. To compare different methods of lentivirus concentration in order to select the best way of providing high-level transduction for generating laboratory CAR-T cells. Materials & Methods. Concentration of lentiviral supernatant was carried out by 4
Ekaterina Konstantinovna Zaikova, K. A. Levchuk, D. Yu. Pozdnyakov, A. A. Daks, A. Yu. Zaritskey, A. V. Petukhov   +5 more
doaj   +1 more source

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement

healthbook TIMES. Oncology Hematology, 2019
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting.
Antonia Maria S. Müller, Alexander Ring
doaj   +1 more source

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Blood Cancer Journal, 2023
CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR T-cell therapies have been developed to reduce the possibility of CD19 ...
Sining Liu, Xinyue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Shengli Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, Depei Wu, Qingya Cui, Xiaowen Tang   +21 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

A Lower Proportion of Regulatory B Cells in Patients with Henoch-Schoenlein Purpura Nephritis. [PDF]

PLoS ONE, 2016
BACKGROUND:Henoch-Schoenlein purpura is the one of most common types of systemic vasculitis that involves impaired renal function and Henoch-Schoenlein purpura nephritis (HSPN).
Xintong Hu, Jiandong Tai, Zhihui Qu, Songchen Zhao, Li Zhang, Man Li, Xiguang Sun, Yanfang Jiang   +7 more
doaj   +1 more source